MedTrace Logo

Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Pain

NCT01298765 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 302

Last updated 2018-08-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether BEMA Buprenorphine is safe in the treatment of chronic pain.

Conditions

Interventions

DRUG

BEMA Buprenorphine

buccal soluble film; applied to the buccal mucosa twice daily

Sponsors & Collaborators

  • BioDelivery Sciences International

    lead INDUSTRY

Principal Investigators

  • Andrew Finn, PharmD · BioDelivery Sciences International

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01298765 on ClinicalTrials.gov